CEO of Immune Pharmaceuticals to Present at BioEquity Europe 2013
EpiCept Reports First Quarter 2013 Operating and Financial Results
Bay Area High School Student Wins BioGENEius Challenge
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
Three ways to separate long-term winners from stocks that fizzle.
Health-care Sector Although the median health-care stock is slightly overvalued in our opinion, we're very excited by the prospects of the health-care sector. Demographics--especially older, wealthier populations--give many of the firms we cover a strong outlook in 2007 and beyond. We're excited ...
Week ending April 27: Quarterly earnings continue to boost market's spirits.